Epitalon Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained

Is 'medical-grade' epitalon a real category?

No. FDA found no USP or National Formulary monograph for epitalon and no approved product containing it, so there is no regulatory or pharmacopeial standard that 'medical-grade' could refer to [1]. Epitalon is not on FDA's compounding lists, and the usual interim policy does not cover it; HHS has proposed a separate, non-binding policy for qualifying epitalon acetate products [2][3][4][5][6].

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base and about 450 g/mol as the acetate [1]. It was designed from the amino-acid content of epithalamin, a polypeptide extract of animal pineal gland, and FDA treats the two as different substances, so epithalamin studies are not epitalon studies [1]. FDA says epitalon first appears to have been synthesized in 1999 [1].

FDA's July 2026 review found no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, nor any product authorized by the European Medicines Agency [1]. Epitalon held an orphan drug designation for retinitis pigmentosa from 2 September 2010 until the designation was withdrawn on 6 January 2016; a designation is not an approval [1].

What the two labels actually describe

Epitalon is sold online as 'research use only' vials of 10 mg to 50 mg, as capsules and as oral sprays, promoted as an anti-aging peptide that lengthens telomeres [1]. A 2015 analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [1][9].

On the compounding side, FDA found no pharmacy that compounds epitalon and no outsourcing facility reporting it [1]. The one documented case is a Kentucky pharmacy that the US Attorney's office reported had compounded and distributed epitalon products from 25 October 2018 to 1 April 2020 [1].

So the two labels differ in who is making the claim, not in what has been established about epitalon. 'Research use only' is a statement printed on the seller's vial, and 'medical-grade' is the seller's own description.

Can a licensed pharmacy compound epitalon?

A state-licensed pharmacy or physician may compound only with a bulk drug substance that complies with a USP or NF monograph if one exists, is a component of an FDA-approved drug product if no monograph exists, or appears on FDA's list of bulk substances that can be used in compounding [4]. Epitalon has no monograph and is not a component of any approved product [1], and it does not appear on that list [2][3][4].

It has also passed through FDA's interim categories. FDA's page on bulk substances that may present significant safety risks, with content dated 22 April 2026, lists epitalon in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them [10]. FDA's stated concern was that it 'has not identified safety-related information regarding epitalon for the proposed route of administration', and it noted that injectable peptides may pose an immunogenicity risk from aggregation and impurities; removal from category 2 was not a finding that epitalon is safe [10].

Epitalon appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated 14 May 2026, or on FDA's list for outsourcing facilities, updated 21 March 2025 [2][3][4]. The category 1 policy, under which FDA generally takes no action against compounders that meet the guidance conditions, does not cover it [2][3][4].

The 2026 advisory vote and the HHS draft policy

FDA staff reviewed epitalon in a July 2026 briefing document and proposed that neither the free base nor the acetate be added to the pharmacy compounding list [1]. Staff evaluated only the insomnia nomination; the anti-aging and telomere uses were not evaluated for lack of information [1]. The stated reasons were that epitalon is not well characterized and has limited historical use, that there was no evidence of effectiveness for insomnia, and that many FDA-approved insomnia drugs already exist; staff also raised an immunogenicity concern for subcutaneous injection [1]. The nominated products were 10 mg/mL and 3000 microgram/mL subcutaneous injections [1].

The Pharmacy Compounding Advisory Committee took up epitalon on 24 July 2026 and voted in favor of adding it to the list, against staff's recommendation [7][5]. That vote is advice only; epitalon is not on the list, and adding it takes formal rulemaking [7][5].

HHS then filed a draft enforcement-discretion policy covering six peptides, among them BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500, under Federal Register document 2026-22192, filed 28 October 2026 with publication scheduled for 30 October 2026 and comments due two weeks after publication [5][6]. For epitalon it covers the acetate form given by subcutaneous or intramuscular injection in intermittent courses, and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds with it if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [5][6].

The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and that HHS may revisit it if a safety signal or a product quality issue arises [5]. It does not put epitalon on any list and does not make it an approved drug [5]. A product made under those conditions would be a compounded drug, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [5].

What human evidence exists

FDA found three human studies of epitalon: two sublingual studies in night-shift workers and one eye-injection study in retinitis pigmentosa, none in insomnia [1]. In the sublingual study as FDA describes it, 75 healthy women aged 40 to 50, mostly night-shift workers, were enrolled and 40 with low melatonin output were split into two groups of 20; a spray delivering about 0.5 mg per day or placebo was given for 20 days, urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition, although no sleep outcomes were measured and blinding was not specified [1].

The retinitis pigmentosa study, published in 2002, reported a 'positive clinical effect in 90% of the cases' in patients with degenerative retinal lesions; its abstract gives no sample sizes or design details [11]. FDA describes the treatment as an injection beside the eye [1].

A 2026 narrative review that searched the literature through 22 September 2026 concluded that human evidence is limited to small physiological or biomarker studies plus that older eye study, that no adequately powered randomized trial has established efficacy, and that epitalon is 'biologically active but clinically unproven' [12].

The telomere result behind most of the marketing comes from cultured human fetal fibroblasts that lack telomerase: adding epitalon induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [8]. That is a cell-culture result, not a human trial, and FDA found no study showing epitalon extends life or slows aging in people [8][1]. In mice, one study gave HER-2/neu transgenic animals 1 microgram per mouse for 5 consecutive days each month and found fewer and smaller mammary tumors than in saline-treated animals [13]. FDA judged the mouse studies of cancer and chromosome damage that it reviewed too limited, with one fixed dose, female mice only and short exposure, to show safety [1].

What is known about safety

FDA found no clinical study that assessed epitalon's safety, and no pharmacokinetic data [1]. Its search of the adverse-event database through 8 December 2025 and of its food and supplement complaint system through 5 December 2025 retrieved no epitalon reports, and FDA concluded there are no clinical data supporting its safety [1]. The 'no side effects' claim traces to a Russian-language abstract that gives no dose, route or number of people [1].

Two concerns are on the record. Injectable peptides may pose an immunogenicity risk from aggregation and impurities [10], and FDA raised that concern specifically for subcutaneous epitalon [1]. FDA also warned that epitalon activates telomerase and lengthens telomeres, that longer telomeres are generally linked to higher cancer risk, and that it therefore has a mechanistic potential to be carcinogenic [1].

Doses sellers list versus doses studied

There is no approved dose [1]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally, in cycles, with one site suggesting a course every four months; these are seller suggestions, not evidence [1]. The human studies FDA found used a sublingual spray delivering about 0.5 mg per day for 20 days, and a parabulbar injection beside the eye for retinitis pigmentosa [1].

What separates a pharmacy-route product from a research vial

The draft HHS policy's conditions include a patient-specific prescription, a single active ingredient, an FDA-registered manufacturer with a certificate of analysis, and a specific label statement [5][6]. Research vials, by contrast, are sold labeled 'research use only' [1]. Even so, epitalon is in none of the three interim categories and on neither federal compounding list, and FDA found no pharmacy compounding it and no outsourcing facility reporting it [1][2][3][4].